Combined Bezafibrate and Medroxyprogesterone Acetate: Potential Novel Therapy for Acute Myeloid Leukaemia

Farhat L. Khanim, Rachel E. Hayden, Jane Birtwistle, Alessia Lodi, Stefano Tiziani, Nicholas J. Davies, Jon P. Ride, Mark R. Viant, Ulrich L. Gunther, Joanne C. Mountford, Heinrich Schrewé, Richard M. Green, Jim A. Murray, Mark T. Drayson, Chris M. Bunce

1 School of Biosciences, University of Birmingham, Birmingham, United Kingdom, 2 Henry Wellcome Building for Biomolecular NMR Spectroscopy, CRUK Institute for Cancer Studies, University of Birmingham, Birmingham, United Kingdom, 3 Division of Cancer Sciences and Molecular Pathology, University of Glasgow, Glasgow, United Kingdom, 4 Department of Developmental Genetics, Max-Planck Institute for Molecular Genetics, Berlin, Germany, 5 Institute of Medical Genetics, Charité-University Medicine Berlin, Berlin, Germany, 6 Centre for Clinical Haematology, Queen Elizabeth Hospital, Birmingham, United Kingdom, 7 Division of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom

Abstract

Background: The majority of acute myeloid leukaemia (AML) patients are over sixty years of age. With current treatment regimens, survival rates amongst these, and also those younger patients who relapse, remain dismal and novel therapies are urgently required. In particular, therapies that have anti-leukaemic activity but that, unlike conventional chemotherapy, do not impair normal haemopoiesis.

Principal Findings: Here we demonstrate the potent anti-leukaemic activity of the combination of the lipid-regulating drug bezafibrate (BEZ) and the sex hormone medroxyprogesterone acetate (MPA) against AML cell lines and primary AML cells. The combined activity of BEZ and MPA (B/M) converged upon the increased synthesis and reduced metabolism of prostaglandin D2 (PGD2) resulting in elevated levels of the downstream highly bioactive, anti-neoplastic prostaglandin 15-deoxy Δ12,14 PGJ2 (15d-PGJ2). BEZ increased PGD2 synthesis via the generation of reactive oxygen species (ROS) and activation of the lipid peroxidation pathway. MPA directed prostaglandin synthesis towards 15d-PGJ2 by inhibiting the PGD2 11β-ketoreductase activity of the aldo-keto reductase AKR1C3, which metabolises PGD2 to 9α11β-PGF2α. B/M treatment resulted in growth arrest, apoptosis and cell differentiation in both AML cell lines and primary AML cells and these actions were recapitulated by treatment with 15d-PGJ2. Importantly, the actions of B/M had little effect on the survival of normal adult myeloid progenitors.

Significance: Collectively our data demonstrate that B/M treatment of AML cells elevated ROS and delivered the anti-neoplastic actions of 15d-PGJ2. These observations provide the mechanistic rationale for the redeployment of B/M in elderly and relapsed AML.

Introduction

Acute myeloid leukaemia (AML) is a devastating cancer characterised by the uncontrolled proliferation, abnormal survival and arrested maturation of leukaemic cells within the bone marrow. The rapid expansion of the leukaemic clone reduces haemopoiesis with loss of normal functioning neutrophils, platelets, and erythrocytes. If untreated, most patients die from infection, bleeding and/or anaemia within weeks of diagnosis.

Current best treatments utilise anthracyclines e.g. daunorubicin or idarubicin, alongside the pyrimidine and purine analogue cytarabine with or without 6-thioguanine [1,2]. These drugs non-selectively inhibit DNA and RNA synthesis and consequently their anti-leukaemic activity is associated with high levels of systemic toxicity, including further reduction of haemopoiesis. Although the current therapies of choice, these agents fail to cure more than two thirds of those patients deemed able to tolerate the therapy [2,3,4]. The problem is further exacerbated by the molecular heterogeneity underlying the disease as well as its distribution within the population. AML incidence increases with age and >75% of patients are older than 60 years of age at diagnosis. These older patients have a much reduced capacity to tolerate high dose chemotherapy and their leukaemia’s are associated with higher frequencies of unfavourable prognostic factors [5]. As a result,
overall survival rates amongst this cohort are dismal with little improvement having been made over the last 20 years [2,3,4,6,7]. This lack of progress coupled with the frail nature of these patients presents them and their clinicians with limited therapeutic options. The majority of elderly patients receive supportive care alone or with non-intensive therapy [4,8]. A review of 36 AML studies involving a total of 12,370 patients (median age 70 yrs) found that the median overall survival for patients receiving supportive care alone was only 7.5 weeks and for those receiving supportive care with non-intensive therapy only 12 weeks [5].

Knowledge of the molecular pathogenesis of AML and other leukemias has led to attempts to develop specific targeted agents and a number of these are now in clinical trial [2,4,9]. However, with the notable exception of all-trans retinoic acid (ATRA) in a subset of AML known as acute promyelocytic leukaemia (APL) [10], and imatinib mesylate (Glivec) and its derivatives in chronic myeloid leukemia (CML) [11], few of these therapies have as yet had a large scale impact. This has led to trials using combinations of targeted therapies [12]. However, the problem of developing targeted therapies for AML is complicated by the inherent heterogeneity and genetic complexity of the disease. Thus whilst attempts at new drug discovery remain important, their low success rates, long time scales and high costs impose serious limitations on progress for improving the outlook in this disease.

‘Drug redeployment’ provides an alternative treatment strategy that is gaining momentum across a broad spectrum of diseases [13,14]. This approach tests the potential of established drugs in new disease settings. We and others have previously demonstrated the individual in vitro anti-proliferative and pro-differentiative actions of the sex steroid medroxyprogesterone acetate (MPA) and lipid regulating fibrate drugs against AML cell lines [15,16,17,18], Burkitts lymphoma (BL) cells [19] and chronic lymphocytic leukaemia (CLL) cells [20]. Here we demonstrate improved combinatorial activity of bezafibrate (BEZ) and MPA (B/M) against AML cell lines and primary AML cells. We demonstrate that the activity of the drugs when combined remains selective against AML cells over normal myeloid blasts. Furthermore we demonstrate that the antitumor activity of B/M against AML cell differs from the activity of the same drugs against CLL cells in that it converges on the increased synthesis and decreased metabolism of prostaglandin D2 (PGD2) and its potently anti neoplastic derivative 15deoxy-A2,12,14-prostaglandin J2 (15d-PGJ2). Several studies have identified potent activities of 15d-PGJ2 against diverse cancers [21,22,23,24,25,26,27,28,29]. The cyclopentenone configuration of this prostaglandin renders it highly reactive facilitating non-enzymatic covalent binding to thiol residues in multiple biological substrates [30,31,32,33,34,35,36,37,38]. The result is modulation of the activity and/or levels of multiple cellular targets, the spectrum of which will be cell context specific but which most likely explain the broad anti tumour activity of 15d-PGJ2. Given its bioactive nature, administration of 15d-PGJ2 is likely to be associated with high toxicity and low bioavailability due to conjugation of 15d-PGJ2 to extracellular targets, including serum proteins [39]. An improved strategy is therefore to promote the accumulation of endogenously formed 15d-PGJ2 within target cells. Since 15d-PGJ2 arises non-enzymatically from PGD2 [40,41] the elevated synthesis of this prostanooid is in turn dependent on the elevation of PGD2. We demonstrate here that in the case of AML, elevation of PGD2 and 15d-PGJ2 with associated anti-leukaemic activity can be achieved with drugs that are available, relatively cheap and familiar in the clinical setting.

Results

The Anti-Leukaemic Actions of BEZ and MPA against AML Cell Lines Are Most Potent When Combined

Figure 1A shows the dose dependent killing of KG1a cells by MPA and BEZ and illustrates the greater individual potency of BEZ. After 10 days treatment with 0.5 mM BEZ cell viability had been reduced to 20% of controls whereas 5 μM MPA had reduced cell viability to just 60% of controls. In BEZ and MPA cross titration experiments, potentiation of killing of KG1a cells was clearly evident with near total loss of viability with 0.5 mM BEZ and 5 μM MPA after 10 days (Figure 1B). Similar results were also observed in HL60 and K562 cells (data not shown) and are consistent with our previous studies in Burkitt’s lymphoma cells [19]. Consequently, all subsequent experiments were performed with 0.5 mM BEZ and 5 μM MPA both when alone and in combination (B/M). The anti-proliferative effects of BEZ and MPA on a panel of cell lines representing diverse forms of AML including U937, NB4 (PML:RARα+ APL), HL-60, K562 (BCR:ABL+ AML blast crisis of chronic myeloid leukaemia) and KG1a cells are shown in Figure 1C and Figure S1. As in KG1a cells, BEZ was the more potent antiproliferative individual agent in U937, NB4 and HL60 cells although neither agent alone was particularly effective against K562 cells. However, B/M treatment was the most potent (p<0.01) at reducing cell number across all the cell lines examined.

BEZ and MPA Variably Induces Differentiation and Apoptosis in Myeloid Cell Lines

The myeloid cell surface antigen CD11b was used in flow cytometry to assess differentiation of U937, NB4, HL60 and KG1a cells. Erythroid differentiation of K562 cells was measured by glycophorin A (Gly A) expression. Consistent with our earlier findings in HL60 cells, MPA alone caused little or no differentiation in any of the cell lines (Figure 2A & Figure S2A) whereas BEZ induced differentiation of U937, NB4 and HL60 cells to varying degrees. Combined B/M treatment induced markedly increased CD11b expression in HL60 cells compared to the individual agents. The combinatorial action of B/M upon HL60 differentiation was confirmed by the reciprocal loss of the more primitive cell marker CD71 (Figure 2B). B/M combined treatment also induced differentiation of U937 and NB4 cells but in these cells there was no increase in B/M over BEZ alone (Figure 2A & Figure S2A). In marked contrast MPA, BEZ and B/M failed to induce either the erythroid or myeloid differentiation of K562 or KG1a cells respectively. This was confirmed by analyses of cell morphology. As shown in Figure 2C, B/M treated NB4 and HL60 cultures clearly contained maturing neutrophils whereas maturing cells were not evident in B/M treated KG1a cultures.

Cell cycle analyses at day 7 identified a marked G1 cell cycle arrest in those cell lines that displayed differentiation in response to B/M (data not shown). In K562, KG1a and U937 but not HL-60 and NB4 cells, cell cycle analyses further identified the accumulation of a sub-G1 fraction, indicative of post apoptotic cells (Figure 2D & Figure S2B). These data indicated that the cell responses to B/M treatment were varied, ranging from strong cell cycle arrest and differentiation to apoptosis. A more detailed comparison of KG1a and HL60 cells confirmed induction of annexin-V labelling (Figure 2E) together with uptake of propidium iodide (PI), consistent with apoptosis in KG1a cells but not in HL60 cells (Figure 2E and 2F).
In Vitro Anti-Leukaemic Activities of BEZ and MPA Are Recapitulated in Primary AML Cells but Not Normal CD34+ve Cells

Primary AML cells also demonstrated in vitro sensitivity to BEZ, MPA and B/M (Figure 3A). At day 8, control cultures originally plated at 1×10⁶ cells/ml contained 1.1±0.13×10⁶ cells/ml. In contrast B/M treated cultures contained 0.52±0.11×10⁶ cells/ml (p<0.0001). Morphological examination of primary AML cultures (not shown) and cytospins (Figure 3B) prepared from B/M treated AML cells indicated that B/M induced loss of cells was most frequently mediated by cell killing rather than overt differentiation.

In marked contrast, treatment with BEZ, MPA or B/M had little effect on normal myeloid progenitors (CD34+ve cells). Unsorted mobilised mononuclear cells which are enriched with CD34+ve myeloid progenitors were treated for 8 days. No changes in cell number were recorded in response to either drug alone and only a small decrease was observed following B/M treatment. Despite this decrease, the proportion of viable CD34+ve cells increased, indicating no significant loss of these cells (Figure 3C). Similarly, treatment of purified mobilised normal donor CD34+ve cells with BEZ, MPA and B/M did not result in apoptosis or frank differentiation. After 8 days, B/M treated cultures contained 89% of the number of viable cells in untreated cultures. Furthermore, although a slight diminution of CD34 fluorescence intensity was observed, overt differentiation as measured by the maturation marker CD11b was not induced (Figure 3D).

MPA Targets AKR1C3 in AML Cells

We and others have shown AML cells to express the aldo-keto reductase AKR1C3 [42,43,44] and our rationale for selecting MPA for redeployment as a potential antileukaemic drug is as an inhibitor of this enzyme [28]. However, although MPA had been shown to inhibit other aldo-keto reductases [45], it had not been directly demonstrated as an inhibitor of AKR1C3. Like other members of the AKR1C subfamily of aldo-keto reductases, AKR1C3 displays substrate promiscuity [46] but amongst the human sub-family possesses unique PGD2-11-ketoreductase activity generating 11β-PGF₂α from PGD₂. Our previous studies have shown that this activity is prominent in AML cells but not detectable in CLL cells [44,20]. MPA inhibited both the cellular AKR1C3 activity in KG1a myeloid cells, as measured by the decreased conversion of 3H-PGD₂ to 3H-11β-PGF₂α (Figure 4A), and the in vitro activity of recombinant-AKR1C3 protein (IC₅₀ = 1.1 μM; Figure 4B). In dose response experiments performed in KG1a cells, the inhibition of AKR1C3 mediated PGD₂ conversion to 11β-PGF₂α mirrored the dose response of reduced cell viability (Figure 4C). Together these data and those from our previous study that identify AKR1C3 as having PGD₂-11-ketoreductase activity in AML cell lines [44] support our model of the action of MPA against AML cells.

The Anti-Leukaemic Activities of BEZ Are Associated with ROS Generation

The original rationale made by ourselves and others for the redeployment of fibrates as anti-AML agents, was based on their activity as ligands for the nuclear receptor PPARγ. However, the required BEZ concentrations observed here suggest an alternative mechanism. BEZ has previously been shown to induce oxidative stress in cells [47,48]. In keeping with this, BEZ treatment of K562 and KG1a cells induced a rapid (within 2 hours, data not shown) and sustained generation of reactive oxygen species (ROS) that was BEZ...
concentration dependent (Figure 5A and 5B). Similar induction of ROS was observed in all AML cell lines when treated with 0.5 mM BEZ (Figure 5C). Finally, using the example of KG1a cells, we observed that cell killing by BEZ tightly correlated with the percentage of ROS positive cells (Figure 5D).

The Actions of BEZ and MPA on AML Cells Converge on the Accumulation of PGD2 and Its Downstream Reactive Product 15d-PGJ2

PGD2 is synthesised from arachidonic acid by both a cyclooxygenase (COX)-dependent pathway [49] and COX-independent, an oxidative stress-dependent, lipid peroxidation-isoprostane pathway [50] (Figure S3). Given that the lipid peroxidation-dependent isoprostane pathway has been shown to be elevated in periods of oxidative stress [51], we postulated that BEZ-induced oxidative stress would result in lipid peroxidation. Consistent with this, 0.5 mM BEZ treatment of AML cell lines labelled with the naturally fluorescent lipid cis-parinaric acid was associated with a significant decrease in fluorescence, indicative of increased lipid peroxidation (Figure 6A). We therefore reasoned that the effects of BEZ and MPA may converge on the elevation of cellular PGD2 via increased lipid peroxidation-mediated synthesis and decreased metabolism by AKR1C3. We also reasoned that as a consequence of increased PGD2 levels, the levels of its potently anti-neoplastic dehydration product 15d-PGJ2 would also be elevated. Indeed, treatment with MPA or BEZ alone and B/M resulted in increased levels of both PGD2 and 15d-PGJ2 in HL60 and KG1a cells (Figure 6B & C). MPA induced 3.3 ± 0.9 fold and 3.8 ± 0.9 fold increases in PGD2 in HL60 and KG1a, respectively as compared to solvent treated control cells (Figure 6B). As may be expected of an inducer of lipid peroxidation and therefore increased isoprostane pathway activity, the effects of BEZ were greater than MPA with 13.7 ± 1.6 and 28.4 ± 9.9 fold increases in PGD2 in HL60 and KG1a, respectively as compared to solvent treated control cells (Figure 6B). B/M gave the most marked elevation especially in HL-60 cells with a 43.4 ± 9.9 fold increase, whereas KG1a had a 35.1 ± 12.2 fold increase. 15d-PGJ2 levels followed a similar trend in both cell lines (Figure 6C).

It has been demonstrated that 15d-PGJ2 itself can potently induce ROS [21]. Consistent with this, treatment of AML cell lines and primary AML cells with 15d-PGJ2 also resulted in the induction of ROS levels similar to those seen in response to B/M (Figure S4). Furthermore, treatment of HL60, K562 and KG1a cells with 15d-PGJ2 recapitulated the antiproliferative actions of B/M (Figure 6E) and the enhanced differentiation of HL-60 cells but not of K562 or KG1a cells (Figure 6F).
Actions of BEZ and MPA Recapitulate Known Activities of 15d-PGJ2

The above observations suggested that the activities of B/M against AML cells may be largely mediated by the generation of 15d-PGJ2. Previous studies have identified multiple mechanisms by which 15d-PGJ2 exerts its anti-neoplastic activity. The nature and range of these actions suggests that the detailed effects of 15d-PGJ2 against individual tumours may show cell context specificity. We studied some of the previously reported activities of 15d-PGJ2 in AML cells following treatment with BEZ and MPA.

Glutathione depletion. The ratio and amounts of reduced glutathione (GSH) and oxidised glutathione (GSSG) are important in regulating the redox state of a cell. Under conditions of oxidative stress, GSH/GSSG levels become depleted and imbalanced, leading to cell differentiation or cell death. Importantly, 15d-PGJ2 concentrations that induce apoptosis and differentiation have been associated with depletion of cellular GSH [21,52]. Furthermore, 15d-PGJ2 levels have been shown to be tightly regulated through GSH-conjugation and subsequent cellular export [53,54,55]. We therefore determined changes in GSH levels following treatment with BEZ, MPA and B/M. Significant decreases in both GSH (Figure 7A) and GSSG (Figures S5 & S6) levels were observed following drug treatment. In the case of GSH reduction the B/M effect was not greater than either drug alone whereas the greatest reduction in GSSG was observed in response to B/M (Figure S6).

PPARγ activation. Amongst the first biological activities ascribed to 15d-PGJ2 was as an activating ligand for the nuclear receptor PPARγ [56,57]. Luciferase reporter assays in transiently transfected HL60 cells identified PPARγ-activation in response to MPA, BEZ and B/M (Figure 7B). Although small, the observed

Figure 3. BEZ and MPA also kill primary AML cells but not normal myeloid progenitors. (A) Primary AML cells were treated for 5 days. Cell numbers were determined by manual counts and are presented as number of cells x 10^6/ml at day 5. The plot shows summary data for 9 individual AMLs and the mean identified by bars. (B) Cell morphology for 2 representative AML samples are shown as determined by Jenner-Giemsma staining of cytopsin slides. (C) Non-sorted mobilised peripheral blood cells were treated with solvent CONT or B/M. Histogram shows representative CD34 staining after 8 days treatment. (D) CD34+ve purified normal mobilised cells were treated with either solvent CONT or B/M for 8 days. The dotplots shown are CD34 and CD11b expression following treatment.

doi:10.1371/journal.pone.0008147.g003
changes in PPARγ-activation mirrored those seen with 5 μM 15d-PGJ2 treatments.

**IkB-accumulation.** 15d-PGJ2 has been shown to regulate NF-κB activity at multiple levels [30,31]. This includes regulation of IkB (inhibitor of κB) protein levels by inhibiting the activity of the IKK (IkB-kinase) complex that targets IkB for ubiquitin-mediated protein degradation [30]. Inhibition of IkB-phosphorylation results in its accumulation and consequent inhibition of NF-κB transcriptional activity. Western blot analysis revealed IkB-accumulation in MPA, BEZ and B/M treated HL60 cells (Figure 7C & D, Figure S7). The pattern of IkB accumulation mirrored that of 15d-PGJ2 accumulation with MPA having the least or little effect, BEZ having a greater effect and the combination being most effective. Similar accumulations were observed in U937 cells and in a sample of primary AML cells, (Figure 7D) however KG1a and NB4 cells did not show an accumulation of IkB (Figure 7C&D, Figure S7). Since 15d-PGJ2 is known to regulate NF-κB transcriptional activity at multiple levels we cannot rule out the possibility that B/M may alter NF-κB in KG1a and NB4 cells by mechanisms other than accumulation of IkB.

The Cellular Activities of BEZ and MPA Are Enhanced by Physiological Levels of Vitamin A and Vitamin D3

When considering the translation of this study into a clinical trial we wished to better understand how to exploit these effects. Since we and others have previously shown that fibrates and MPA each separately enhance ATRA and 1α,25(OH)2 vitamin D3 (D3) induced HL-60 cell differentiation [15,17,58] we reasoned that where the combined action of B/M results in differentiation this may be reciprocally limited in the absence of ATRA and D3. In an attempt to mimic physiological levels of ATRA and D3 that might be expected in patients with adequate daily vitamin A and D intake, we treated HL60 cells with B/M together with 1 nM ATRA, 1 nM D3 and the combination (ATRA/D3). As in
Figure 2A, B/M alone caused differentiation in ~20% of HL60 cells, 1 nM ATRA + 1 nM D3 (ATRA/D3) alone caused differentiation in ~33% as measured by expression of the differentiation marker CD11b at day 7 (Figure 8A). However, morphologically relatively few cells had reached terminal neutrophil differentiation (Figure 8B). Addition of ATRA or D3 individually to B/M resulted in a significant increase in differentiated cells (Figure 8A). However, the addition of B/M together with ATRA/D3 resulted in ~90% of cells expressing increased CD11b and morphologically all cells had differentiated into polymorphonuclear neutrophils and/or undergone apoptosis (Figure 8A & B) demonstrating strong complementary interactions between B/M and physiological levels of ATRA and D3. Prolonged survival and differentiation was rarely seen in primary AML cells however, when it did occur, we also observed complementarity between B/M and ATRA/D3. This is illustrated in the primary AML (non-APL) sample shown in Figure 8C. CD11b expression was detected in 4.5% of control cells compared to 17.5% in ATRA/D3 treated cells. B/M alone induced CD11b expression in 32%, which was further increased to 46% when cells were treated with B/M & ATRA/D3 (Figure 8C). Interestingly, the addition of ATRA/D3 did not interfere with induction of ROS by B/M indicating that these agents were working by complementary actions (Figure 8D).

Discussion
Drug redeployment has already demonstrated great promise in haematopoietic malignancies including, thalidomide in myeloma [59] and valproic acid and arsenic trioxide in AML [60,61]. However, few studies have sought to redeploy combinations of old drugs that deliver greater potency than either drug alone. We demonstrate here that exploiting some understanding of the mechanisms of drug actions against cancer cells allows the rational testing of such potentially beneficial combinations.

The anti-neoplastic activities of 15d-PGJ2 have been described in many reports [21–29], however few studies have sought...
Figure 6. BEZ and MPA modulate PGD2 and 15d-PGJ2 levels. (A) 0.5 mM BEZ induced lipid peroxidation was measured by treating cells labelled with the naturally fluorescent lipid cis-parinaric acid. Data is presented as % fluorescence units (FU) compared to solvent control cells for N = 5 experiments for each cell line. Mean is indicated by black bar. (B & C) Endogenous levels of (B) PGD2 and (C) 15d-PGJ2 were determined in HL60 and KG1a cells by ELISA following 2 hours treatment. Prostaglandin levels are shown relative to untreated controls for a minimum of 4 experiments. Mean is indicated by black bar. Statistics: * p<0.05. (D) ROS induction was determined by staining with DCFDA and flow cytometry in HL60, KG1a and primary AML samples (n = 3) after 48 hours treatment with CONT, B/M or 10 μM 15d-PGJ2. Data shown are mean±sem. Individual datapoints are shown in Figure S4. (E & F) HL60, K562 and KG1a cells were treated for 7 days with either solvent control or 5 μM 15d-PGJ2. Data is shown from a minimum of N = 3 experiments. Mean is indicated by black bar. (E) Cell viability was assessed by Alamar blue and calculated as % of control cells. (F) Differentiation was assessed by CD11b staining of HL60 and KG1a and GlyA staining of K562 cells followed by flow cytometry. Statistics: * p<0.01.

doi:10.1371/journal.pone.0008147.g006
strategies for utilising this potential. Although a novel cycloanthan-
nylproline derivative, Fuligocandin B, has been shown to induce
15d-PGJ2 production in treated cells the compound has yet to
undergo toxicity testing in humans [62]. Here, we demonstrate
that 15d-PGJ2 and its precursor, PGD2, can be elevated in AML
cells using already available drugs with good safety profiles. BEZ
treatment mediated sustained ROS generation with associated
lipid peroxidation, downstream synthesis of PGD2 and conse-
quently, generation of 15d-PGJ2. MPA, further elevated PGD2
and 15d-PGJ2 levels by inhibiting the metabolism of PGD2 by
AKR1C3 (Figure S8).

15d-PGJ2 is a cyclopentenone prostaglandin. These prostaglan-
dins have unsaturated α,β ketone moieties that allow non-enzymatic
covalent modification of cellular targets [63]. It is this reactive
nature that is thought to be responsible for their potent and wide-
ranging properties [63,64]. Proteomic approaches have identified
the conjugation of 15d-PGJ2 with many protein targets including
multiple components of mitochondria, the cytoskeleton and also
transcriptional networks such as NF-κB [30–38]. Importantly, B/
M treatment of AML cell lines and primary AMLs recapitulated
some of the known anti-neoplastic activities of 15d-PGJ2. However
these actions were not uniform across all the cell types tested.
Similarly, we observed differential apoptotic and differentiation
responses to B/M in both AML cell lines and primary AML cells.
These variations may reflect the molecular heterogeneity of AML
and the consequent contextual actions of 15d-PGJ2.

In contrast, 15d-PGJ2 also generated ROS in all AML cell lines
and primary AML cells tested. It may therefore be that B/M

treatment induces a cycle of direct and secondary 15d-PGJ2-
mediated ROS generation thereby perpetuating a cycle of
 glutathione depletion and oxidative stress. The importance of
ROS as well as 15d-PGJ2 in mediating the anti-leukaemic activity of
B/M is highlighted by our recent NMR based metabolomics study
of B/M treated AML cell lines [18]. It has been shown that ROS
mediates the direct chemical conversion of α-ketoglutarate to
succinate [65,66,67]. Notably, our metabolomics study identified

Figure 7. Downstream consequences of elevating 15d-PGJ2 levels. (A) Elevating 15d-PGJ2 levels results in lowering of reduced-glutathione
(GSH). HL60 cells were treated for 48 hours and μg GSH per mg of protein measured. Data shown is from 4 experiments and the mean is indicated by
a black bar. (B) PPARγ transcriptional activity was measured after 14 hours treatment of PPRE-luciferase reporter plasmid and pRenilla luciferase
transfected HL60 cells with either MPA, BEZ, the combination (B/M) or 5 μM 15d-PGJ2 (PGJ2). Data shown is luciferase activity compared to control
untreated cells for N = 5 experiments. Mean is indicated by black bar. (C&D) IκB levels were determined by western blotting of cells treated for
14 hrs. Levels were normalised for loading by β-actin westerns. (C) Representative western blot results for HL60, KG1a and a primary AML (D) Graph
represents mean±SEM of densitometry performed on a minimum of N = 3 experiments for each cell line. All individual datapoints are shown in Figure
S7. Statistics: * p<0.05.
doi:10.1371/journal.pone.0008147.g007
drug mediated imbalances within the TCA cycle including the depletion of α-ketoglutarate and the accumulation of succinate [18]. This effect was recapitulated in cell extracts by the application of the ROS hydrogen peroxide. Therefore the antileukaemic actions of B/M against AML are complex and most likely mediated by separate and overlapping actions of both 15d-PGJ2 and ROS.

Although our studies have focused upon the accumulation of PGD2 and 15d-PGJ2 in B/M treated AML cells, it should not be ignored that part of the activity of MPA against AML cells may also be mediated by the diminution of 11β-PGF2α (Figure S8) and future studies should address this possibility. Furthermore, since the anti-neoplastic activities of 15d-PGJ2 have been demonstrated in multiple tumour models [21–29], the potential of B/M based therapy may also extend beyond AML into other 15d-PGJ2 sensitive tumours. Our observations that B/M has greater efficacy against CLL, BL and now AML cells than either BEZ or MPA alone would appear to support this contention. However, it is important to note that although we have demonstrated that CLL cells express AKR1C3 we were unable to demonstrate AKR1C3 PGD2-11-ketoreductase activity in these cells [20]. These observations indicate that the substrate promiscuity of AKR1C3 is of real biological importance and has implications for its functions in different cell contexts. Hence, further studies are required to determine how B/M and particularly MPA or other AKR1C3 inhibitors exert anti tumour activities in different tumour settings.

In summary our findings support the investigation of B/M as novel therapy in elderly and relapsed AML. We have instigated such a trial, the results of which will be published in the near future. Given the low direct and supportive care costs of these agents, and their activity against multiple tumour types this study identifies an affordable potential anti-cancer therapy in developing countries where fiscal and other restraints limit the availability of conventional chemotherapy.

Materials and Methods

Reagents
Bezafibrate (0.5 M in DMSO), MPA (5 mM in ethanol), ATRA (1 mM in DMSO), and 1α, 25(OH)2 vitamin D3 (1 mM in...
ethanol (Sigma Aldrich). PGD$_2$ and 15d$\Delta^{12,14}$PGJ$_2$ (Affiniti, UK) were dissolved in DMSO to yield 20 $\mu$M stocks and stored at $-20^\circ$C.

In Vitro Recombinant AKR1C3 Activity Assay
Recombinant N-terminal His-tagged recombinant AKR1C3 was produced as previously described [68]. Enzyme reactions (1 ml-volumes) contained 15 $\mu$g recombinant AKR1C3, 4 $\mu$M phenanthrenequinone (Sigma, UK), 150 $\mu$M NADPH (Sigma) and 0–100 $\mu$M MPA in 50 mM potassium phosphate buffer (pH 6.5) at 35°C and measured as the rate of change of pyridine nucleotide absorbance at 340 nm.

Primary Cells, Cell Lines and Treatments
HL-60, NB4, U937, K562 and KG1a myeloid cell lines were maintained in RPMI 1640 medium supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS) and penicillin/streptomycin (Gibco, Invitrogen Ltd, UK). Unless specified otherwise, 1x10$^6$ cells in 4 ml was treated with solvent control, 5 $\mu$M MPA, 0.5 mM BEZ or the combination B/M. 1 $\mu$M ATRA+1 $\mu$M 15d$\Delta^{12,14}$PGJ$_2$ (D3) (Sigma, UK), 10 $\mu$M PGD$_2$ or 5–10 $\mu$M 15d-PGJ$_2$ were added where specified. Primary AML mononuclear cell preparations were prepared using Ficoll Paque-Plus (Pharmacia Biotech, UK) from presentation aspirates and peripheral blood samples provided after informed consent and ethical committee approval from ongoing phase II trials currently undertaken within the University of Birmingham Hospitals NHS Trust and from the MRC AML 15 phase III trial. The resultant AML blast preparations were cultured at 1x10$^6$ cells/ml in RPMI 1640 supplemented with 1% (v/v) ITS$^+$ (VWR, UK), IL3 (1 ng/ml) and SCF (10 ng/ml) (both R&D Systems, UK). For treatments, primary AML cells were set at 1x10$^6$ cells/ml with either solvent control, 5 $\mu$M MPA, 0.5 mM (500 $\mu$M) BEZ or B/M, ± 1 $\mu$M ATRA+D3. Viability was determined by manual cell counts and cytospin preparations made for analysis of morphology. Normal donor mobilised peripheral blood samples were provided under ethical approval and informed consent by the National Blood Service, Stem Cell Laboratories, Birmingham, UK, and treated as for primary AML cells.

$^3$H-PGD$_2$ Turnover Analysis by Thin Layer Chromatography
PGD$_2$ turnover in intact cells was determined similarly to that described previously [28]. Briefly, 2x10$^6$ KG1a cells were incubated with 0.2 $\mu$Ci/1.3pmoles $^3$H-PGD$_2$ (Amersham Biosciences) in warm PBS for 9 hours. Prostaglandin extracts were prepared from supernatants and separated on silica gel/TLC plates before reading on a Bioscan plate reader. Prostanoids were identified by their co-migration with known standards (Biomol International L.P., UK) visualized by placing in a sealed tank filled with iodine vapor for approximately 5 minutes.

Lipid Peroxidation Assay
2x10$^5$ cells at 2.5 x 10$^5$/ml were treated at 37°C for 2 hours with the addition of 10 $\mu$M cis-parinaric acid (a naturally fluorescent lipid) for the last 30 mins. Cells were harvested and lipids extracted in the dark for 1 hour with isoamyl alcohol + 0.05% butylated hydroxytoluene. Fluorescence readings were taken at 320 nm$_{excitation}$/415 nm$_{emission}$. Background fluorescence of lipids extracted from unlabelled control cells was subtracted from all values and data presented as % fluorescence units (FU) compared to solvent control cells.

Assessment of Accumulation of ROS
Cells were treated for 14 hours at 37°C and 10 $\mu$M carboxy-H$_2$DCFDA (Molecular Probes, Invitrogen, UK) added to cells for the final 45 mins. Following incubation, cells were washed with PBS and analysed by flow cytometry (Becton Dickinson FACSCalibur and Becton Dickinson Cell Quest software).

Prostaglandin ELISAs
Prostaglandin D2-MOX ELISA kit (Cayman Chemicals, USA) and 15A$^{12,14}$Prostaglandin J2 Enzyme Immunoassay Kit (Assay Designs, Inc., USA) were used to determine prostaglandin levels. 5x10$^5$ cells were treated for 2 hours. Following treatment, cells were harvested with 1 ml culture media and homogenised using a Precellys 24 ceramic bead based homogenisation system. Prostaglandins were extracted using C18 reverse phase extraction columns (Chromabond, Fisher, UK) and levels determined by ELISA.

Measurement of GSH Levels
3x10$^5$ cells were treated at 2.5x10$^5$/ml, cell pellets prepared and GSH levels determined as described previously [69].

PPRE Reporter Assays
Briefly, 2x10$^5$ HL-60 cells were transfected with 2.5 $\mu$g p-xACO-Luciferase (kind gift from Prof Bert Vogelstein, John Hopkins, USA) and 0.5 $\mu$g pRenilla-luciferase (Promega, UK) using Solution V and file T19 on the AMAXA Nucleofector I system. Transfected cells were allowed to recover for 14 hrs and then treated for 24 hrs. Cells were harvested and luciferase measured using the Dual-Glo® Luciferase Assay Kit (Promega, UK) according to manufacturer’s instructions.

Western Blot Analyses
Cells treated with drugs for 14 hrs were lysed in RIPA buffer and 30 $\mu$g proteins separated by SDS-PAGE. Proteins were transferred to Immobilon-P membrane (Millipore Corp, Bedford, MA, USA) and probed with 1/1000 dilution of anti-6kB (Santa Cruz, USA). Detection was by anti-rabbit-horse radish peroxidise (HRP) diluted 1/1000 and ECL using Supersignal West Pico Chemiluminescent substrate (Pierce, USA). Loading controls used anti β-actin antibody (Sigma UK) diluted 1/25000 and anti-mouse-HRP secondary at 1/25000. Densitometry was performed using ImageJ software (http://rsb.info.nih.gov/ij/).

Measurement of Relative Number of Viable Cells
Myeloid cell lines were treated for 7 days with feeding every 2 days. Numbers of viable cells in triplicate 100 $\mu$l aliquots of cultures were determined using CellTiter-Blue® reagent (CellTiter-Blue® Cell Viability Assay, Promega, UK). Readings were adjusted for feeding schedules over the course of treatment.

Assessment of Cell Differentiation
Myeloid cell lines were treated for 7 days with feeding and retreating every 2 days. Analysis of differentiation antigen expression was by flow cytometry (Becton Dickinson FACSCalibur and Becton Dickinson Cell Quest software) using FITC-CD71 and PE-CD11b (Becton Dickinson) conjugated antibodies for HL60, U937, NB4 and KG1a cells. FITC-Glycoporphrin-A was used to determine erythroid differentiation of K562 (Serotec, UK).

Assessment of Apoptosis by Annexin-V
Phosphotidylserine cell surface expression was assessed using Annexin-V FITC kit (Becton Dickinson, UK). Analyses were
carried out by flow cytometry on a Becton Dickinson FACS Calibur utilising Cell Quest Pro software (Becton Dickinson, UK).

**Jenner Giemsa Staining of Slides**
Cytospins were prepared from 75–100 μl of culture. Slides were air-dried, methanol fixed and stained; first with Jenner staining solution (VWR, UK) diluted 1/3 in 1 mM sodium phosphate buffer pH 5.6 (5 mins) and second with Giemsa stain (VWR, UK) diluted 1/20 in 1 mM sodium phosphate buffer pH 5.6 (10 mins). Slides were dried and then mounted onto coverslips using DePex (VWR, UK).

**Statistics**
Data were analysed using SPSS v15 and the non-parametric Mann-Whitney U test. Unless stated in the legend, the statistics shown in figures are all compared to control cultures.

**Supporting Information**

**Figure S1** Cell viability is reduced in Myeloid cell lines treated with BEZ, MPA or B/M. Cell viability as % of solvent treated controls was determined in 5 myeloid cell lines by Alamar Blue assay following treatment with either solvent control, 0.5 mM BEZ, 5 μM MPA or the combination (B/M) for 7 days. Cell viability was calculated for treatments relative to solvent treated controls after readings had been adjusted for feeding regimens over the 7 days of treatment. Mean is indicated by the black bars. Statistics *p<0.01.

**Figure S2** Effect of BEZ, MPA and B/M on myeloid cell lines. (A) Differentiation was measured by flow-cytometry using the myeloid differentiation antigen CD11b for HL60, NB4, U937, KG1a cells and the erythroid antigen Glycophorin-A for differentiation of K562. Scatter plots show data from a minimum of N = 3 experiments. Mean is indicated by black bar. (B) % Sub-G1 events were measured by flow cytometry cell cycle analysis of propidium iodide stained cells following 7 days treatment. Scatter plot shows data from a minimum of N = 3 experiments. Mean is indicated by black bar.

**Figure S3** PGD₂ synthesis, metabolism and non-enzymatic conversions towards 15dΔ²,⁶ 12,14PGJ₂. Adapted from Gao et al, 2003 (JBC 278: 20479–89). PGD₂ is highly unstable and rapidly undergoes non-enzymatic conversions to form 15dΔ²,⁶ 12,14PGJ₂ in the absence of AKR1C3. Solid arrows and dotted arrows indicate enzyme mediated and non-enzymatic conversions respectively.

**Figure S4** ROS induction in myeloid cell lines and primary AMLs. Reactive oxygen species (ROS) induction was determined by staining with carboxy-H2 DCFDA and flow cytometry in HL60, KG1a and primary AML samples after 48 hours treatment with CONT, B/M or 10 mM 15d-PGJ₂. Data shown is N = 4 for HL60 and KG1a and N = 3 primary AMLs. Mean is indicated by black bar. Statistics *p<0.01.

**Figure S5** 1H-1H 2D correlation spectroscopy (COSY) NMR spectrum of KG1a cells extracts. Expanded region (2.6–4.8 ppm) of 1H-1H 2D COSY 45 (CORrelation SpectroscopY) NMR spectrum acquired on dried polar extracts of KG1a cells (solvent control treatment) redissolved in 99.9% D2O (GOSS Scientific Instruments Ltd, Essex UK). 2D COSY experiments were carried out using 800 MHz Varian spectrometer equipped with a cryogenically cooled probe using a gradient-selected coherence transfer pathway (@COSY45) (Hard, John & Plant, 1991, J Mag Reson, 93: 666) with 16 transients of 8192 complex data points, 256 increments, and a spectral width of 0 kHz in both dimensions. The highlighted peaks (red lines) are due to oxidized (GSSG) and reduced (GSH) glutathione.

**Figure S6** 1H 1D NMR spectrum of KG1a cells extracts. Cells were treated for 24 hours and polar extracts analysed by NMR. Extraction of metabolites from cells pellets was performed using a modified Bligh-Dyer procedure. Dried polar extracts were redissolved in 90% H₂O/10% D₂O (GOSS Scientific Instruments Ltd, Essex UK) with phosphate buffer (100 mM, pH 7), containing 0.5 mM TMSP. A 500 MHz Bruker spectrometer equipped with a cryogenically cooled probe was used for 1H 1D data acquisition. The water resonance was suppressed using excitation sculpting (Hwang & Shaka, 1998, J Magn Reson, 135: 280). 1D spectra were acquired using a 60° pulse, a 5 kHz spectral width, a relaxation delay of 3 s with 128 transients. 3 different sections (2.15–2.22, 2.50–2.62, and 2.95–3.02 ppm) of the 1H 1D NMR spectrum of KG1a cell extracts containing glutathione peaks. A minimum of 12 replicates for each treatment (black, solvent control; red, MPA, green BEZ, blue B/M) are shown. The inset depicts the average spectrum of 12 replicates expanded between 2.15–2.22 ppm.

**Figure S7** I-kappa B levels are reduced in some myeloid cell lines following treatment with B/M. IkB levels were determined by western blotting of cells treated with either solvent control, 0.5 mM BEZ, 5 μM MPA or the combination for 14 hrs. Levels were normalised for loading by β-actin westerns and densitometry. Scatter plots show all datapoints for a minimum of N = 3 experiments for each cell line. Means are indicated by black bars. Statistics *p<0.05.

**Author Contributions**
Conceived and designed the experiments: FLK JPR MRV UG HS JCM HS MTD CB. Wrote the paper: FLK REH JB AL ST NJD JPR MRV UG JCM HS MTD CB. Contributed reagents/materials/analysis tools: JPR RMG MTD CB. Analyzed the data: FLK REH JB AL ST NJD JPR MRV UG JCM HS MTD CB. Performed the experiments: FLK REH JB AL ST NJD MTD CB. Performed the experiments: FLK REH JB AL ST NJD MTD CB. Wrote the paper: FLK REH NJD MTD CB.

**References**

1. Craig CM, Schiller GJ (2008) Acute myeloid leukemia in the elderly: conventional and novel treatment approaches. Blood Rev 22: 221–234.

2. Estey E (2007) Acute myeloid leukemia and myelodysplastic syndromes in older patients. J Clin Oncol 25: 1906–1915.
3. Kohut HE, Coutre SE (2008) Optimizing therapy for acute myeloid leukemia. J Natl Comp Care Nerve 6: 1003–1016.

4. Tallman MS, Carde RE, Ebert T, Mendelsohn R, Luebber M (2006) Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 91: 1513–1522.

5. Burnett AK, Milligan D, Goldstone A, Prentice A, Goldstone A, et al. (2006) Antitumor effects of older patients with acute myeloid leukemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol 135: 318–332.

6. Kroll MJ, McGivern J, Blumberg J, Shearman D, Maguire J, et al. (2008) Recent advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer 113: 1933–1952.

7. Tallman MS (2004) Acute promyelocytic leukemia as a paradigm for targeted therapy. Semin Hematol 41: 27–32.

8. Desmouliere A (2008) Is the focus moving toward a combination of targeted drugs? Best Pract Res Clin Haematol 21: 629–637.

9. Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3: 673–683.

10. Cooney MJ, Sullivan CA, Kohane IS, Goldstein RM, et al. (2007) Potency of myeloid differentiation by anti-inflammatory agents, by steroids, and by retinoic acid involves a single intracellular target, probably an enzyme of the retinoid receptor family. Biochem Biophys Res Commun 311: 139–145.

11. Scatena R, Nozza G, Sole PD, Rumi C, Puglioni P, et al. (1999) Bezafibrate as differentiating factor of human myeloid leukemia cells. Cell Death Differ 6: 761–767.

12. Burnet AK, Mclachlan JA, Prabhuj K (2009) 15-Deoxy-Delta(12,14)-prostaglandin J2 inhibits HIV-1 transactivating protein, Tat, through covalent modification. FASEB J.

13. Aldini G, Carini M, Vistoli G, Shibata T, Kusano Y, et al. (2007) Identification of actin as a 15-deoxy-Delta12,14-prostaglandin J2 target in neuroblastoma cells: mass spectrometric, computational, and functional approaches to investigate the effect on cytoskeletal derangement. Biochemistry 46: 2507–2517.

14. Tiziani S, Lodi A, Khanim FL, Viant MR, Bunce CM, et al. (2009)

15. Nilsson A, Farrants AK, Nesland JM, Finstad HS, Pedersen JI (1995)

16. Scatena R, Lodi A, Khanim FL, Viant MR, Bunce CM, et al. (2009) The aldo-keto reductase AKR1C3 is a novel suppressor of cell neuronal apoptosis. Proc Natl Acad Sci U S A 99: 7367–7372.

17. Burnett AK, Ebert T, Mendelsohn R, Luebber M (2006) Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 91: 1513–1522.

18. Burnett AK, Macute U (2006) Treatment of older patients with acute myeloid leukemia or acute leukemia. Semin Hematol 43: 96–106.

19. Burnett AK, Milligan D, Goldstone A, Prentice A, Goldstone A, et al. (2006) Antitumor effects of older patients with acute myeloid leukemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol 135: 318–332.

20. Burnett AK, Macute U (2006) Treatment of older patients with acute myeloid leukemia or acute leukemia. Semin Hematol 43: 96–106.

21. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, et al. (2009) Treatment of acute promyelocytic leukemia as a paradigm for targeted therapy. Semin Hematol 41: 27–32.

22. Desmouliere A (2008) Is the focus moving toward a combination of targeted drugs? Best Pract Res Clin Haematol 21: 629–637.

23. Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3: 673–683.

24. Cooney MJ, Sullivan CA, Kohane IS, Goldstein RM, et al. (2007) Potency of myeloid differentiation by anti-inflammatory agents, by steroids, and by retinoic acid involves a single intracellular target, probably an enzyme of the retinoid receptor family. Biochem Biophys Res Commun 311: 139–145.

25. Scatena R, Nozza G, Sole PD, Rumi C, Puglioni P, et al. (1999) Bezafibrate as differentiating factor of human myeloid leukemia cells. Cell Death Differ 6: 761–767.

26. Burnet AK, Mclachlan JA, Prabhuj K (2009) 15-Deoxy-Delta(12,14)-prostaglandin J2 inhibits HIV-1 transactivating protein, Tat, through covalent modification. FASEB J.

27. Aldini G, Carini M, Vistoli G, Shibata T, Kusano Y, et al. (2007) Identification of actin as a 15-deoxy-Delta12,14-prostaglandin J2 target in neuroblastoma cells: mass spectrometric, computational, and functional approaches to investigate the effect on cytoskeletal derangement. Biochemistry 46: 2507–2517.

28. Tiziani S, Lodi A, Khanim FL, Viant MR, Bunce CM, et al. (2009) The aldo-keto reductase AKR1C3 is a novel suppressor of cell neuronal apoptosis. Proc Natl Acad Sci U S A 99: 7367–7372.

29. Burnett AK, Macute U (2006) Treatment of older patients with acute myeloid leukemia or acute leukemia. Semin Hematol 43: 96–106.

30. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, et al. (2009) Treatment of acute promyelocytic leukemia as a paradigm for targeted therapy. Semin Hematol 41: 27–32.

31. Desmouliere A (2008) Is the focus moving toward a combination of targeted drugs? Best Pract Res Clin Haematol 21: 629–637.

32. Ashburn TT, Thor KB (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3: 673–683.

33. Cooney MJ, Sullivan CA, Kohane IS, Goldstein RM, et al. (2007) Potency of myeloid differentiation by anti-inflammatory agents, by steroids, and by retinoic acid involves a single intracellular target, probably an enzyme of the retinoid receptor family. Biochem Biophys Res Commun 311: 139–145.

34. Scatena R, Nozza G, Sole PD, Rumi C, Puglioni P, et al. (1999) Bezafibrate as differentiating factor of human myeloid leukemia cells. Cell Death Differ 6: 761–767.

35. Burnet AK, Mclachlan JA, Prabhuj K (2009) 15-Deoxy-Delta(12,14)-prostaglandin J2 inhibits HIV-1 transactivating protein, Tat, through covalent modification. FASEB J.

36. Aldini G, Carini M, Vistoli G, Shibata T, Kusano Y, et al. (2007) Identification of actin as a 15-deoxy-Delta12,14-prostaglandin J2 target in neuroblastoma cells: mass spectrometric, computational, and functional approaches to investigate the effect on cytoskeletal derangement. Biochemistry 46: 2507–2517.

37. Tiziani S, Lodi A, Khanim FL, Viant MR, Bunce CM, et al. (2009) The aldo-keto reductase AKR1C3 is a novel suppressor of cell neuronal apoptosis. Proc Natl Acad Sci U S A 99: 7367–7372.
55. Paumi CM, Wright M, Townsend AJ, Morrow CS (2003) Multidrug resistance protein (MRP) 1 and MRP3 attenuate cytotoxic and transactivating effects of the cyclopentenone prostaglandin, 15-deoxy-Delta(12,14)prostaglandin J2 in MCF7 breast cancer cells. Biochemistry 42: 5429–5437.

56. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, et al. (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83: 813–819.

57. Forman BM, Tontonoz P, Chen J, Bruns RP, Spiegelman BM, et al. (1995) 15-Deoxy-delta.12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 83: 803–812.

58. Fenton SL, Drayson MT, Hewison M, Vickers E, Brown G, et al. (1999) Clofibric acid: a potential therapeutic agent in AML and MDS. Br J Haematol 105: 448–451.

59. Breitkreutz I, Anderson KC (2008) Thalidomide in multiple myeloma—clinical trials and aspects of drug metabolism and toxicity. Expert Opin Drug Metab Toxicol 4: 973–985.

60. Kurendgen A, Gattermann N (2007) Valproic acid for the treatment of myeloid malignancies. Cancer 110: 943–954.

61. Tallman MS (2008) The expanding role of arsenic in acute promyelocytic leukemia. Semin Hematol 45: S25–29.

62. Hasegawa H, Yamada Y, Koniyama K, Hayashi M, Ishibashi M, et al. (2007) A novel natural compound, a cycloanthranilylproline derivative (Fuligocandin B), sensitizes leukemia cells to apoptosis induced by tumor necrosis factor related apoptosis-inducing ligand (TRAIL) through 15-deoxy-Delta 12, 14 prostaglandin-J2 production. Blood 110: 1664–1674.

63. Stamatakis K, Perez-Sala D (2006) Prostanoids with cyclopentenone structure as tools for the characterization of electrophilic lipid-protein interactomes. Ann N Y Acad Sci 1091: 548–570.

64. Milne GL, Musiek ES, Morrow JD (2003) The cyclopentenone (A2/J2) isoprostanes—unique, highly reactive products of arachidonate peroxidation. Antioxid Redox Signal 7: 210–220.

65. Fedotcheva NI, Sokolov AP, Komashova MN (2006) Nonezymatic formation of succinate in mitochondria under oxidative stress. Free Radic Biol Med 41: 56–64.

66. Mailloux RJ, Berzin R, Lemire J, Singh R, Chouinier DR, et al. (2007) The tricarboxylic acid cycle, an ancient metabolic network with a novel twist. PLoS ONE 2: e690.

67. Schumacker PT (2006) Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 10: 175–176.

68. Lovering AL, Ride JP, Bunce CM, Desmond JC, Cummings SM, et al. (2004) Crystal structures of prostaglandin D(2) 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs ibufenac acid and indomethacin. Cancer Res 64: 1802–1810.

69. Hodges NJ, Green RM, Chipman JK, Graham M (2007) Induction of DNA strand breaks and oxidative stress in HeLa cells by ethanol is dependent on CYP2E1 expression. Mutagenesis 22: 189–194.